(Q27852713)

English

Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma (English)

1 reference

13 November 2016

0 references

1 reference

based on heuristic

inferred from title

Dominique Figarella-Branger

10

object named as

Dominique Figarella-Branger

0 references

L'Houcine Ouafik

11

object named as

L'houcine Ouafik

0 references

Françoise Boudouresque

2

object named as

Françoise Boudouresque

0 references

8

object named as

Marc Sanson

0 references

author name string

Emeline Tabouret

1

0 references

Maryline Barrie

3

0 references

Mona Matta

4

0 references

Celine Boucard

5

0 references

Anderson Loundou

6

0 references

Antoine Carpentier

7

0 references

Philippe Metellus

9

0 references

Olivier Chinot

12

0 references

publication date

March 2014

0 references

0 references

16

0 references

392-9

0 references

3

0 references

Molecular mechanisms and clinical applications of angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

7 April 2017

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

7 April 2017

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

7 April 2017

Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

29 September 2017

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

29 September 2017

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

29 September 2017

Bevacizumab: current updates in treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

29 September 2017

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

29 September 2017

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

29 September 2017

Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

29 September 2017

Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

29 September 2017

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

29 September 2017

Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

29 September 2017

Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

2 June 2018

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

2 June 2018

Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922517

2 June 2018

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT226

21 January 2018

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT226

21 January 2018

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT226

21 January 2018

A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT226

21 January 2018

High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT226

21 January 2018

Quantitative analysis of matrix metalloproteinase-2 mRNA expression in central and peripheral regions of gliomas.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT226

21 January 2018

Matrix metalloproteinase 2 attenuates brain tumour growth, while promoting macrophage recruitment and vascular repair.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT226

21 January 2018

Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/24327581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urinary biomarkers predict brain tumor presence and response to therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24327581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24327581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24327581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/NEUONC/NOT226

0 references

1 reference

13 November 2016

1 reference

13 November 2016

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852713&oldid=2015154962"